In-Cell-Art results with two Top 10 Pharma will be presented at the 16th Annual Discovery on Target on September 25-28 2018 in Boston
In-Cell-Art (ICA), a biotechnology company specialized in nanocarrier technologies named Nanotaxi® designed to unlock the promise of nucleic acids to... View Article
In-Cell-Art, the Institut Pasteur and BioNet-Asia announce the collaborative development of a dengue vaccine candidate successful in preclinical study
Nantes – Paris – France, 19th of June, 2018 – In-Cell-Art (ICA), a biotechnology company specialized in nanocarrier technologies, BioNet-Asia... View Article
Bioregate Forum 2018 #2nd edition
Bioregate Forum is the “must attend” European gathering for key players in the Regenerative Medicine sector: 3 days dedicated to... View Article
Affilogic is financing a proof of concept thanks to the Boost4Health programme
Affilogic,a member of Atlanpole Biotherapies, has received a € 5000 voucher as part of the Boost4Health programme. This support has... View Article
A thymic cell study programme for developing an ambitious transplant strategy
This programme is led by Dr. Matthieu Giraud, a specialist in immunology, genetics and bioinformatics. Having spent a number of... View Article
In-Cell-Art announces a contract with one of top 5 Global Pharmas to discover potential antibodies medicines
Nantes – France, 24 of May , 2018 – In-Cell-Art (ICA), a member of Atlanpole Biotherapies, a biotechnology company specialized in... View Article
Hemarina announces positive preclinical proof of concept results on lung preservation before transplantation
Hemarina, a member of Atlanpole Biotherapies, the marine biotechnology company specializing in the development of extracellular universal oxygen carriers for unmet... View Article
HORAMA Appoints Dr Russell Greig as New Chairman of the Board
Paris, May 15, 2018 – Horama, a French biotech company based in Paris and Nantes, is a spin-off of Philippe... View Article
OSE Immunotherapeutics receives the Euronext Tech 40 Label
Nantes, France, April 23 2018, OSE Immunotherapeutics, a member of Atlanpole Biotherapies, has received the Euronext Tech 40 Label and... View Article
InFlectis BioScience IFB-088 enters phase-1 clinical trial
InFlectis BioScience SAS, a member of Atlanpole Biotherapies, a drug discovery company committed to the development of innovative therapeutics harnessing... View Article